PEG-Alkyl Gold Nanoparticles for Keratinocyte-Targeted Skin Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for psoriasis, including systemic delivery and phototherapy, pose risks of infection and adverse effects, while topical treatments lack specificity for skin cells and understanding of skin-nano interactions hampers nanoparticle development for effective delivery.
Innovation Solution
A composition of gold nanoparticles with a polyethylene glycol (PEG) shell and alkyl functional groups is designed for optimal distribution and entry into keratinocytes, using specific chain lengths and loadings to enhance skin permeability and anti-inflammatory effects, combined with toll-like receptor 7/8 ligands for modulating psoriasis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional topical treatments (corticosteroids and vitamin analogs) are used for mild psoriasis, then treatment effectiveness is improved, but adverse effects such as skin atrophy occur
Solution Approach 1:
The patent applies local quality by designing nanoparticles with specific surface properties (PEG coating, alkyl chain length, charge distribution) that enable selective accumulation and action at the skin lesion site. The nanoparticles are engineered to target psoriatic plaques specifically, delivering therapeutic agents locally while minimizing systemic absorption and adverse effects in surrounding skin tissue.
Solution Approach 2:
The patent utilizes parameter changes by systematically varying nanoparticle characteristics including core size (1-100 nm), PEG shell thickness, alkyl chain length (C6-C24), and surface charge to optimize delivery efficiency. These parameter adjustments enable the nanoparticles to penetrate the stratum corneum effectively while maintaining safety, resolving the contradiction between effectiveness and skin atrophy.
2Reliability
If systemic delivery methods (methotrexate, retinoids, cyclosporin, biologic agents) are used for moderate to severe psoriasis, then treatment effectiveness is improved, but the risk of infection increases due to chronic immunosuppression
Solution Approach 1:
The patent transitions from systemic delivery to local nanoparticle delivery, where therapeutic agents are confined to the psoriatic lesion site through nanoparticle accumulation. This localized action reduces the overall immunosuppressive burden on the body, thereby maintaining effective psoriasis treatment while minimizing the risk of opportunistic infections associated with chronic systemic immunosuppression.
Solution Approach 2:
The patent extracts the therapeutic action from the systemic circulation and concentrates it at the site of disease through nanoparticle targeting. By removing the need for high-dose systemic immunosuppressants and replacing them with localized nanoparticle delivery, the approach maintains treatment effectiveness while eliminating the harmful systemic side effects including infection risk.
3Reliability
If phototherapy is used for moderate to severe psoriasis, then treatment effectiveness is improved, but the treatment time is excessive
Solution Approach 1:
The patent replaces the physical mechanism of phototherapy (ultraviolet light exposure) with a chemical/nanoparticle-based mechanism. The nanoparticles deliver therapeutic agents directly to the skin cells through permeation and endocytosis, eliminating the need for repeated clinic visits and extended treatment durations associated with phototherapy, while maintaining comparable or superior effectiveness.
4Productivity
If nanoparticles are designed for enhanced skin permeability and keratinocyte entry, then delivery effectiveness is improved, but the complexity of nanoparticle design and optimization increases
Solution Approach 1:
The patent applies segmentation by dividing the nanoparticle design into distinct functional modules: a core (1-100 nm) containing the therapeutic payload, a PEG shell providing steric stabilization and permeability, and surface-modified alkyl chains enabling keratinocyte interaction. This modular segmentation allows independent optimization of each component to achieve effective delivery without overwhelming complexity in the overall design.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively targets and permeates skin cells, reducing psoriasis symptoms by optimizing nanoparticle distribution and enhancing therapeutic efficacy without systemic side effects.
Implementation Method 1
The composition is configured for optimal skin permeability or for an optimal entry into keratinocytes
Implementation Method 2
Nanoparticles (NPs) offer immense potentials for transdermal delivery and treating skin diseases, because they can be engineered to diffuse through the skin upon topical application
Data Source
AI summary
A composition of an anti-psoriatic drug and methods of applying the anti-psoriatic drug for transdermal delivery of nanoparticles and entry into skin cells are provided. The composition of the anti-psoriatic drug includes a core having at least one gold nanoparticle, a shell of polyethylene glycol (PEG) strands conjugated to the core, and a plurality of alkyl groups conjugated to the shell of PEG strands. Moreover, a chain length of the plurality of alkyl groups, chain loading of the plurality of alkyl groups, or a diameter of the core is configured to optimize a distribution of the composition in the skin cells. The distribution may include skin permeability or an entry into keratinocytes. Further, methods of modulating effectiveness of the anti-psoriatic drug for inhibiting development of a psoriasis phenotype or for treatment of the psoriasis phenotype are provided.